Despite encouraging clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from PBMs. Such insurers are frequently creating https://zubairhirx154740.csublogs.com/49967393/company-s-drug-faces-is-dealing-with-pbm-challenges-a-review-of-access-battles